3 Reasons Spark Therapeutics Is a Buy After Its Crash

After Spark Therapeutics and competitor BioMarin Therapeutic (NASDAQ: BMRN) updated investors on the progress that they're making developing competing gene therapies for hemophilia, investors knocked more than one third off Spark Therapeutics' (NASDAQ: ONCE) valuation yesterday. The sell-off was undeniably painful for existing investors, but it could be creating an opportunity for new investors to pick up shares in this gene therapy leader.

Here's why Spark Therapeutics shares fell, and three reasons investors ought to consider adding this biotech to their portfolios.

According to the World Federation of Hemophilia, there are 151,000 people with hemophilia A and nearly 30,000 people with hemophilia B worldwide. An inability to produce a protein necessary for clotting blood makes hemophilia patients continuously at risk of severe bleeding events and life-threatening hemorrhages. In hemophilia A patients, it's coagulant factor VIII that's missing or under-produce,; and in hemophilia B, it's coagulant factor IX.

Continue reading

Source: Fool.com